ArticlePloS one2019
Latanoprost could exacerbate the progression of presbyopia.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Sex Differences in Preferred Under-Correction of Contact Lenses and Their Potential Relevance to Presbyopia Management.Clinical optometry · 2026Article
- Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System.Scientific reports · 2025Article
- Presbyopia Progression From the Age of 40 to 79 Years in Glaucoma Patients Treated With Prostaglandin F Receptor Agonists.Translational vision science & technology · 2025Article
- Comparison of Presbyopia Between Glaucoma Patients Using Prostaglandin F Receptor Agonists and Fixed Combination Therapy.Clinical optometry · 2025Article
- Near Add Power of Glaucoma Patients with Early Presbyopia.Journal of clinical medicine · 2024Article
- Symptomatic Presbyopia may Develop Earlier in Patients With Glaucoma-A Cross-Sectional Retrospective Cohort Study.Translational vision science & technology · 2024Article
- Presbyopia, Dry Eye, and Retinal Thickness in the Middle-Aged Population: Focusing on Sex Differences.Clinical optometry · 2024Article
- Pharmacological treatment of presbyopia: A systematic review.European journal of translational myology · 2022Article
- Short Tear Breakup Time Could Exacerbate the Progression of Presbyopia in Women.BioMed research international · 2022Article
- Presbyopia developed earlier during the COVID-19 pandemic.PloS one · 2021Article
- Sleep and subjective happiness between the ages 40 and 59 in relation to presbyopia and dry eye.PloS one · 2021Article
- Tear Break-Up Time and Seasonal Variation in Intraocular Pressure in a Japanese Population.Diagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstaglandin analogues (PG) reduce intra-ocular pressure by enhancing uveoscleral flow at the ciliary body, which controls accommodation via the ciliary muscle. We investigated the effect of PG on accommodation and presbyopia progression in glaucoma patients.
methodsWe conducted a clinic-based, retrospective, cross-sectional study. Inclusion criteria were bilateral phakic patients aged 40-69 years with best corrected visual acuity better than 20/30. Exclusion criteria were any disease affecting vision other than glaucoma and history of ocular surgery. Subjects with no prescription or vision-affecting disease served as controls (n = 260). The glaucoma patients were prescribed eye drops containing 0.005% latanoprost for more than six months (n = 23). We measured the binocular near add power at a distance of 30 cm in both groups and compared the results using Kaplan-Meier analysis.
resultsThe mean age (± SD) of the control subjects was 51.5 ± 5.2 years and 39% were male. Similarly, the glaucoma patients had a mean age of 51.0 ± 7.2 years and 39% were male. There were no significant differences in age, gender, intra-ocular pressure, spherical equivalent, astigmatism, or anisometropia between groups. Survival analysis indicated that the glaucoma patients in this study reached the endpoint (near add power of +3.00 D) significantly earlier than control patients (P = 0.0001; generalized Wilcoxon test).
conclusionsExacerbation of presbyopia progression in glaucoma patients is a potential side effect of latanoprost eyedrops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.